Diagnosis of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) at Risk for Advanced Fibrosis in a Real-World Primary Care Setting: A Cross-Sectional Study

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Journal of general internal medicine

• Publication date

  2025-07-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11606-025-09659-4PMID 40624322PMCID PMC12855709
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metabolic Dysfunction–Associated Steatotic Liver Disease

  2025cited by this paper
• Objective measures of cardiometabolic risk and advanced fibrosis risk progression in primary care patients with metabolic dysfunction-associated steatotic liver disease.

  2024cited by this paper
• Statin prescriptions and progression of advanced fibrosis risk in primary care patients with MASLD

  2024cited by this paper
• AASLD Practice Guideline on blood-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.

  2024cited by this paper
• Current status and future trends of the global burden of MASLD.

  2024cited by this paper
• A multisociety Delphi consensus statement on new fatty liver disease nomenclature

  2023influential reference
• AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease.

  2023influential reference
• A multi-society Delphi consensus statement on new fatty liver disease nomenclature.

  2023cited by this paper
• 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2024.

  2023cited by this paper
• Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective

  2023cited by this paper
• Waist-hip ratio is superior to BMI in predicting liver-related outcomes and synergizes with harmful alcohol use

  2023cited by this paper
• Statin prescribing patterns in patient-centered medical home patients with NAFLD.

  2023cited by this paper
• Undiagnosed Diabetes in U.S. Adults: Prevalence and Trends.

  2022cited by this paper
• A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.

  2022cited by this paper
• American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).

  2022influential reference
• 2019 global NAFLD prevalence - A systematic review and meta-analysis.

  2021cited by this paper
• Administrative Coding in Electronic Health Care Record‐Based Research of NAFLD: An Expert Panel Consensus Statement

  2021cited by this paper
• Advanced liver fibrosis and the metabolic syndrome in a primary care setting

  2021cited by this paper
• Preparing for the NASH epidemic: A call to action

  2021cited by this paper
• Preparing for the NASH Epidemic: A Call to Action

  2021cited by this paper
• Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.

  2021cited by this paper
• Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.

  2021cited by this paper
• Advancing the global public health agenda for NAFLD: a consensus statement

  2021cited by this paper
• Nonalcoholic Fatty Liver Disease Underdiagnosis in Primary Care: What Are We Missing?

  2021cited by this paper
• Standards of Medical Care in Diabetes-2022 Abridged for Primary Care Providers.

  2021cited by this paper
• The four dimensions of contestable AI diagnostics - A patient-centric approach to explainable AI

  2020cited by this paper
• Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening

  2020cited by this paper
• Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data

  2020cited by this paper
• Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.

  2020cited by this paper
• The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis.

  2019cited by this paper
• The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

  2018cited by this paper
• The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

  2018influential reference
• Hypertension Management in Diabetes: 2018 Update

  2018cited by this paper
• Positive Predictive Value of International Classification of Diseases, 10th Revision, Codes for Cirrhosis and Its Related Complications

  2018cited by this paper
• Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.

  2017cited by this paper
• Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis

  2016influential reference
• Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.

  2015cited by this paper
• Predictive value of ALT levels for non‐alcoholic steatohepatitis (NASH) and advanced fibrosis in non‐alcoholic fatty liver disease (NAFLD)

  2013cited by this paper
• World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

  2013cited by this paper
• Birmingham and Lambeth Liver Evaluation Testing Strategies (BALLETS): a prospective cohort study.

  2013cited by this paper
• Use of Administrative Claims Data for Identifying Patients with Cirrhosis

  2013cited by this paper
• Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database.

  2008cited by this paper
• FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest

  2007cited by this paper
• Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data

  2005cited by this paper
• WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI: Ethical Principles for Medical Research Involving Human Subjects

  2001cited by this paper

• No citing papers are available for this paper.